Browse RELN

Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF02014 Reeler domain
Function

Extracellular matrix serine protease that plays a role in layering of neurons in the cerebral cortex and cerebellum. Regulates microtubule function in neurons and neuronal migration. Affects migration of sympathetic preganglionic neurons in the spinal cord, where it seems to act as a barrier to neuronal migration. Enzymatic activity is important for the modulation of cell adhesion. Binding to the extracellular domains of lipoprotein receptors VLDLR and LRP8/APOER2 induces tyrosine phosphorylation of DAB1 and modulation of TAU phosphorylation (By similarity).

> Gene Ontology
 
Biological Process GO:0001764 neuron migration
GO:0001941 postsynaptic membrane organization
GO:0003002 regionalization
GO:0007215 glutamate receptor signaling pathway
GO:0007270 neuron-neuron synaptic transmission
GO:0007389 pattern specification process
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007611 learning or memory
GO:0007612 learning
GO:0007613 memory
GO:0007616 long-term memory
GO:0008306 associative learning
GO:0008347 glial cell migration
GO:0010001 glial cell differentiation
GO:0010469 regulation of receptor activity
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0016358 dendrite development
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0021510 spinal cord development
GO:0021511 spinal cord patterning
GO:0021517 ventral spinal cord development
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021700 developmental maturation
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0021795 cerebral cortex cell migration
GO:0021799 cerebral cortex radially oriented cell migration
GO:0021800 cerebral cortex tangential migration
GO:0021801 cerebral cortex radial glia guided migration
GO:0021819 layer formation in cerebral cortex
GO:0021885 forebrain cell migration
GO:0021987 cerebral cortex development
GO:0022029 telencephalon cell migration
GO:0022030 telencephalon glial cell migration
GO:0022604 regulation of cell morphogenesis
GO:0022898 regulation of transmembrane transporter activity
GO:0030335 positive regulation of cell migration
GO:0030900 forebrain development
GO:0031346 positive regulation of cell projection organization
GO:0031503 protein complex localization
GO:0031929 TOR signaling
GO:0032006 regulation of TOR signaling
GO:0032008 positive regulation of TOR signaling
GO:0032409 regulation of transporter activity
GO:0032411 positive regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032414 positive regulation of ion transmembrane transporter activity
GO:0032793 positive regulation of CREB transcription factor activity
GO:0033555 multicellular organismal response to stress
GO:0033674 positive regulation of kinase activity
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035249 synaptic transmission, glutamatergic
GO:0035418 protein localization to synapse
GO:0038026 reelin-mediated signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0042391 regulation of membrane potential
GO:0043113 receptor clustering
GO:0043270 positive regulation of ion transport
GO:0044708 single-organism behavior
GO:0045666 positive regulation of neuron differentiation
GO:0045860 positive regulation of protein kinase activity
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048167 regulation of synaptic plasticity
GO:0048265 response to pain
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050769 positive regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050775 positive regulation of dendrite morphogenesis
GO:0050795 regulation of behavior
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0050890 cognition
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051057 positive regulation of small GTPase mediated signal transduction
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051272 positive regulation of cellular component movement
GO:0051668 localization within membrane
GO:0051962 positive regulation of nervous system development
GO:0051966 regulation of synaptic transmission, glutamatergic
GO:0051968 positive regulation of synaptic transmission, glutamatergic
GO:0060074 synapse maturation
GO:0060078 regulation of postsynaptic membrane potential
GO:0060079 excitatory postsynaptic potential
GO:0060291 long-term synaptic potentiation
GO:0060996 dendritic spine development
GO:0060997 dendritic spine morphogenesis
GO:0060998 regulation of dendritic spine development
GO:0060999 positive regulation of dendritic spine development
GO:0061001 regulation of dendritic spine morphogenesis
GO:0061003 positive regulation of dendritic spine morphogenesis
GO:0061097 regulation of protein tyrosine kinase activity
GO:0061098 positive regulation of protein tyrosine kinase activity
GO:0061564 axon development
GO:0072578 neurotransmitter-gated ion channel clustering
GO:0072657 protein localization to membrane
GO:0090128 regulation of synapse maturation
GO:0090129 positive regulation of synapse maturation
GO:0097061 dendritic spine organization
GO:0097114 NMDA glutamate receptor clustering
GO:0097119 postsynaptic density protein 95 clustering
GO:0097120 receptor localization to synapse
GO:0097475 motor neuron migration
GO:0097476 spinal cord motor neuron migration
GO:0097477 lateral motor column neuron migration
GO:0097485 neuron projection guidance
GO:0098815 modulation of excitatory postsynaptic potential
GO:0099565 chemical synaptic transmission, postsynaptic
GO:0099601 regulation of neurotransmitter receptor activity
GO:1900006 positive regulation of dendrite development
GO:1900271 regulation of long-term synaptic potentiation
GO:1900273 positive regulation of long-term synaptic potentiation
GO:1900449 regulation of glutamate receptor signaling pathway
GO:1900451 positive regulation of glutamate receptor signaling pathway
GO:1902076 regulation of lateral motor column neuron migration
GO:1902078 positive regulation of lateral motor column neuron migration
GO:2000147 positive regulation of cell motility
GO:2000273 positive regulation of receptor activity
GO:2000310 regulation of N-methyl-D-aspartate selective glutamate receptor activity
GO:2000311 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity
GO:2000463 positive regulation of excitatory postsynaptic potential
GO:2000969 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity
GO:2001222 regulation of neuron migration
GO:2001224 positive regulation of neuron migration
Molecular Function GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
GO:0070325 lipoprotein particle receptor binding
GO:0070326 very-low-density lipoprotein particle receptor binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
Reactome R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-8866376: Reelin signalling pathway
R-HSA-8855121: VLDL interactions
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RELN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RELN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RELN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5430.227
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3390.0711
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0280.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6290.141
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9330.605
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2470.912
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0450.265
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.550.689
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.8480.182
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0680.936
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6290.568
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0360.918
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RELN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277333.316.416.90.0954
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275933.316.916.40.101
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211747.611.835.80.0336
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)865016.733.30.301
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131146.29.137.10.0778
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.414.83.60.751
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.715.47.30.689
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.514.3-1.81
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RELN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RELN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RELN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RELN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RELN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RELN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRELN
Namereelin
Aliases RL; PRO1598; ETL7
Chromosomal Location7q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RELN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.